755039-54-4

Basic information

• Product Name: 6(5H)-Pteridinone, 2-chloro-8-cyclopentyl-7-ethyl-7,8-dihydro
• Synonyms: 6(5H)-Pteridinone, 2-chloro-8-cyclopentyl-7-ethyl-7,8-dihydro;6(5H)-Pteridinone, 2-chloro-8-cyclopentyl-7-ethyl-7,8-dihydro-, (7R)-;(R)-2-chloro-8-cyclopentyl-7-ethyl-7,8-dihydropteridin-6(5H)-one
• CAS NO: 755039-54-4
• Molecular Formula: C₁₃H₁₇ClN₄O
• Molecular Weight: 280.75
• EINECS: 1308068-626-2
• Product Categories: API intermediates
• Mol File: 755039-54-4.mol
• Article Data: 24

Chemical Properties

• Boiling Point: 512.7±45.0 °C(Predicted)
• Appearance: /
• Density: 1.286±0.06 g/cm3(Predicted)
• PKA: 10.53±0.40(Predicted)
• CAS DataBase Reference: 6(5H)-Pteridinone, 2-chloro-8-cyclopentyl-7-ethyl-7,8-dihydro(CAS DataBase Reference)
• NIST Chemistry Reference: 6(5H)-Pteridinone, 2-chloro-8-cyclopentyl-7-ethyl-7,8-dihydro(755039-54-4)
• EPA Substance Registry System: 6(5H)-Pteridinone, 2-chloro-8-cyclopentyl-7-ethyl-7,8-dihydro(755039-54-4)

Safety Data

• Hazardous Substances Data: 755039-54-4(Hazardous Substances Data)

Usage

Description

6(5H)-Pteridinone, 2-chloro-8-cyclopentyl-7-ethyl-7,8-dihydro is a heterocyclic chemical compound with the molecular formula C13H15ClN2O. It features a pteridine ring and a chlorine atom, and is a derivative of pteridinone. Characterized by a chloro-substituted cyclopentyl group at the 2-position and an ethyl group at the 7-position, this white to off-white crystalline solid is sparingly soluble in water. Its unique structure and properties render it a promising candidate for pharmaceutical research and development, particularly in the creation of new drugs with pteridine-based structures.

Uses

Used in Pharmaceutical Industry:
6(5H)-Pteridinone, 2-chloro-8-cyclopentyl-7-ethyl-7,8-dihydro serves as a key intermediate in the synthesis of pteridine-based drugs. Its distinctive chemical structure allows for the development of pharmaceuticals with potential applications in various therapeutic areas, such as anti-inflammatory, anti-cancer, and anti-viral treatments. 6(5H)-Pteridinone, 2-chloro-8-cyclopentyl-7-ethyl-7,8-dihydro's ability to be modified and its potential to interact with biological targets make it an attractive molecule for medicinal chemistry and drug design.

Upstream product

• 1081998-93-7 C₁₃H₁₆Cl₂N₄O₃ 
• 755039-53-3 (R)-methyl 2-((2-chloro-5-nitropyrimidin-4-yl)(cyclopentyl)-amino)butanoate 
• 876126-66-8 C₁₅H₂₁ClN₄O₄ 
• 755039-52-2 (R)-methyl 2-(cyclopentylamino)butanoate 
• 120-92-3 cyclopentanone 

Downstream Products

• 755039-55-5 (R)-2-chloro-8-cyclopentyl-7-ethyl-5-methyl-7,8-dihydropteridin-6(5H)-one 
• 755039-56-6 (R)-4-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxybenzoic acid 
• 1344728-02-4 (R)-N-(2-aminoethyl)-4-(8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-ylamino)-3-methoxybenzamide 
• 755038-02-9 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)benzamide 

Relevant articles and documents

Design, synthesis and biological evaluation of novel pteridinone derivatives possessing a sulfonyl moiety as potent dual inhibitors of PLK1 and BRD4

The simultaneous inhibition of PLK1 and BRD4 by a single molecule could lead to the development of an effective therapeutic strategy for a variety of diseases in which PLK1 and BRD4 are implicated. Herein, two series of novel pteridinone derivatives possessing a sulfonyl moiety were designed, synthesized and evaluated for their biological activity. Most compounds exhibited moderate to excellent cytotoxic activity against HCT116, PC3 and BT474 cell lines. Among them, the most promising compound B2 showed high antiproliferative effects on the three cell lines with IC50 values of 0.30 μM, 1.82 μM and 1.69 μM, respectively. In the enzymatic assay, B2 was identified as a potent PLK1 and BRD4 dual inhibitor (PLK1 IC50 = 6.3 nM, BRD4 IC50 = 179 nM). Further explorations in bioactivity were conducted to clarify the anticancer mechanism of compound B2. The results showed that compound B2 obviously inhibited the proliferation of HCT116 cell lines, induced a great decrease in the mitochondrial membrane potential leading to apoptosis of HCT116 cells and arrested the G2 phase of HCT116 cells.

Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer

Targeting poly(ADP-ribose) polymerase1/2 (PARP1/2) is a promising strategy for the treatment of pancreatic cancer with breast cancer susceptibility gene (BRCA) mutation. Inducing the deficiency of homologous recombination (HR) repair is an effective way t

Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors

Protein kinase inhibitors and epigenetic regulatory molecules are two main kinds of anticancer drugs developed in recent years. Both kinds of drugs harbor their own advantages and disadvantages in the treatment of cancer, and the development of small mole